Morgan Stanley Reiterates Equal-Weight on BioNTech, Maintains $124 Price Target
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Matthew Korn has reiterated an Equal-Weight rating on BioNTech (NASDAQ:BNTX) and maintained a $124 price target.

June 20, 2023 | 12:58 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley analyst Matthew Korn reiterates an Equal-Weight rating on BioNTech (NASDAQ:BNTX) and maintains a $124 price target.
The news of Morgan Stanley reiterating an Equal-Weight rating on BioNTech and maintaining a $124 price target is neutral for the stock. It indicates that the analyst believes the stock is fairly valued and does not expect significant price movement in the short term. The relevance is high as the news directly pertains to BioNTech, and the importance is moderate as it is an analyst rating update. The confidence in the analysis is high as it is based on the information provided in the article.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100